State of Alaska Department of Revenue Has $55.25 Million Stake in AbbVie Inc. $ABBV

Key Points

• State of Alaska Department of Revenue trimmed its stake in AbbVie by 5% to 241,809 shares, worth $55.25 million, making it the fund’s 20th-largest holding (≈0.6% of assets).
• AbbVie cut its Q1 and FY2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), a key near-term negative catalyst that has weighed on sentiment.
• AbbVie announced a quarterly dividend of $1.73 per share (annualized $6.92, yield 3.3%), payable May 15 with an ex-dividend date of April 15, despite a high payout ratio (~293%).

State of Alaska Department of Revenue decreased its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 241,809 shares of the company's stock after selling 12,740 shares during the period. AbbVie accounts for about 0.6% of State of Alaska Department of Revenue's holdings, making the stock its 20th largest position. State of Alaska Department of Revenue's holdings in AbbVie were worth $55,250,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Diversified Trust Co grew its stake in shares of AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company's stock worth $13,215,000 after acquiring an additional 10,891 shares during the last quarter. Permanent Capital Management LP acquired a new stake in shares of AbbVie in the third quarter worth $720,000. Railway Pension Investments Ltd grew its stake in shares of AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company's stock worth $197,723,000 after acquiring an additional 211,800 shares during the last quarter. World Investment Advisors grew its stake in shares of AbbVie by 9.4% in the third quarter. World Investment Advisors now owns 113,925 shares of the company's stock worth $26,378,000 after acquiring an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co grew its stake in shares of AbbVie by 93.4% in the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company's stock worth $7,434,000 after acquiring an additional 15,502 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
• Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
• Positive Sentiment: Analysts and features continue to highlight AbbVie's successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit
• Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie's guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
• Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie's guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
• Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

AbbVie Price Performance

AbbVie stock opened at $208.22 on Monday. The company has a market capitalization of $368.16 billion, a PE ratio of 88.23, a price-to-earnings-growth ratio of 0.75 and a beta of 0.38. AbbVie Inc. has a one year low of $168.54 and a one year high of $244.81. The business has a 50 day simple moving average of $220.35 and a 200 day simple moving average of $224.04.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie's revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is 293.22%.

Insider Activity at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is owned by company insiders.

Analyst Ratings Changes

ABBV has been the topic of several research analyst reports. Evercore lowered their price objective on shares of AbbVie from $232.00 to $228.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 4th. Morgan Stanley lifted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a report on Thursday, February 5th. BMO Capital Markets reissued an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Berenberg Bank set a $275.00 price objective on AbbVie in a report on Tuesday, January 20th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $223.00 price objective on shares of AbbVie in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average target price of $253.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.